Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor

Digestive Diseases and Sciences

Volumn 50, Issue 10, 2005, Pages 1921-1926

  Oda, Kayoko ^a   Iwakiri, Ryuichi ^a   Hara, Megumi ^a   Watanabe, Kazuyo ^a   Danjo, Akiko ^a   Shimoda, Ryo ^a   Kikkawa, Atsushi ^a   Ootani, Akifumi ^a   Sakata, Hiroyuki ^a   Tsunada, Seiji ^a   Fujimoto, Kazuma ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Acid regurgitation; Heartburn; Los Angeles Classification; Odynophagia

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DYSPHAGIA; ENDOSCOPY; ESOPHAGITIS; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PH MEASUREMENT; PRIORITY JOURNAL; RELAPSE; STOMACH ACID SECRETION; STOMACH PH; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DEGLUTITION DISORDERS; ESOPHAGITIS, PEPTIC; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 26244463050     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2962-5     Document Type: Article

References (30)

1. De Vault KR, Castell DO: The practice parameters committee of the American College of gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 14:34-42, 1994
2. Armstrong D, Bennett JR, Blum AL, Dent J, DeDombal FT, Galmiche JP, Lundell L, Margulies M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 111:85-92, 1996
3. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L: Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles Classification. Gut 45:172-180, 1999
4. Nguyen NQ, Holloway RH: Gastroesophageal reflux disease. Curr Opin Gastroenterol 19:373-378, 2003
5. Okamoto K, Iwakiri R, Mori M, Hara M, Oda K, Danjo A, Ootani A, Sakata H, Fujimoto K: Clinical symptoms in endoscopic esophagitis: evaluation in 8031 adult subjects. Dig Dis Sci 48:2237-2241, 2003
6. Tauber S, Gross M, Issing W: Association of laryngopharyngeal symptoms with gastroesophageal reflux disease. Laryngoscope 112:879-886, 2002
7. Woo P, Noodzij P, Ross J: Association of esophageal reflux and globus symptoms: comparison of laryngoscopy and 24-hour pH manometry. Otolaryngol Head Neck Surg 115:502-507, 1996
8. Shaker R, Milbrath M, Ren J, Toohill R, Hogan WJ, Li Q, Hofmann CL: Esophagopharyngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 109:1575-1582, 1995
9. Amin MR, Postma GN, Johnson P, Digges N, Koufman JA: Proton pump inhibitor resistance in the treatment of laryngopharyngeal reflux. Otolaryngol Head Neck Surg 125:374-378, 2001
10. Maton PN, Burton ME: Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs 57:855-870, 1999
11. Tytgat GN: Treatment of mild and severe cases of GERD. Aliment Pharmacol Ther 16 (Suppl 4):73-78, 2002
12. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL: Acid inhibition on the first day of dosing comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17:1507-1514, 2003
13. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effect of rabeprazole, lansoprazole and omeprazole on intragastric p in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 16:1811-1817, 2002
14. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L: Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 16:445-454, 2002
15. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL: A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 16:479-485, 2002
16. Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H, Yagi J, Komazawa Y, Mihara T, Katsube T, Lujishiro H, Shizuku T, Hattori S, Yamamoto S, Kinoshita Y: Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol 18:1392-1398, 2003
17. Ishizaki T, Horai Y: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 13 (Suppl 3):27-36, 1999
18. Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 14:1259-1266, 2000
19. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao L, Kosuge K, Nakawawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 15:1929-1937, 2001
20. Lachman L, Howden CW: Twenty-four-hour intragastric pH: Tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 95:57-61, 2000
21. Fackler WK, Ours TM, Vaezi ML, Richter JE: Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 122:625-632, 2002
22. Adachi K, Komazawa Y, Fujishiro H, Mihara T, Ono M, Yuki M, Kawamura A, Karim RMA, Amano Y, Kinishita Y: Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol 38:830-835, 2003
23. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morcutti A, Miller N, Bardhan KD: A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 17:343-351, 2003
24. Fass R, Fennerty MB, Johnson C, Camargo L, Samplimer RE: Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol 28:36-39, 1999
25. Talley NJ, Fullerton S, Junghard O, Wiklund I: Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 96:1998-2004, 2001
26. Young MA, Rose S, Reynolds JC: Gastrointestinal manifestations of scleroderma: Rheum Dis Clin North Am 22:797-823, 1996
27. Postma GN, Tomek MS, Belafsky PC, Koufman JA: Esophageal motor function in laryngopharyngeal reflux is superior to that in classic gastroesophageal reflux disease. Ann Otol Rhinol Laryngol 110:1114-1116, 2001
28. Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, Kondo M: A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 14 (Suppl 1):74-81, 2000
29. Hamaguchi M, Fujiwara Y, Takashima T, Hayakawa T, Sasaki E, Shiba M, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Higuchi K, Arawawa T: Increased expression of cytokines and adhesion molecules in rat chronic esophagitis. Digestion 68:189-197, 2003
30. Fujiwara Y, Higuchi K, Hamaguchi M, Takashima T, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Arakawa T: Increased expression of transforming growth factor-alpha and epidermal growth factor receptors in rat chronic reflux esophagitis. J Gastroenterol Hepatol 19:521-527, 2004